Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly and Co BDR | B3 | Healthcare | Pharmaceuticals | R$3.98T | 62.5x | 0.82 | R$148.01 | -4.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson Johnson BDR | B3 | Healthcare | Pharmaceuticals | R$2.12T | 17x | -0.42 | R$58.59 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AbbVie DRC | B3 | Healthcare | Pharmaceuticals | R$1.89T | 79.1x | -2.78 | R$66.99 | -3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk AS | B3 | Healthcare | Pharmaceuticals | R$1.70T | 19.5x | 0.93 | R$47.50 | -3.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca | B3 | Healthcare | Pharmaceuticals | R$1.27T | 28.6x | 1.25 | R$67.10 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis AG DRC SA | B3 | Healthcare | Pharmaceuticals | R$1.27T | 17.5x | -1.31 | R$64.54 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck Co Inc BDR | B3 | Healthcare | Pharmaceuticals | R$1.13T | 11.4x | 0.02 | R$55.85 | -5.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen Inc BDR | B3 | Healthcare | Pharmaceuticals | R$831.03B | 24.4x | 0.45 | R$55.21 | -2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer Inc BDR | B3 | Healthcare | Pharmaceuticals | R$743.22B | 16.5x | 0.01 | R$32.63 | -4.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences DRC | B3 | Healthcare | Pharmaceuticals | R$696.02B | 20.4x | 0.02 | R$280.15 | -3.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Vertex Pharmaceuticals DRC | B3 | Healthcare | Pharmaceuticals | R$657.46B | -212.9x | 2.09 | R$630.87 | -11.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bristol Myers Squibb Company BDR | B3 | Healthcare | Pharmaceuticals | R$551.95B | 17.9x | 0.1 | R$271 | -4.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
McKesson | B3 | Healthcare | Pharmaceuticals | R$509.87B | 32.5x | -24.95 | R$1,021.11 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GlaxoSmithKline | B3 | Healthcare | Pharmaceuticals | R$447.80B | 18.8x | -0.62 | R$42.95 | -3.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Zoetis | B3 | Healthcare | Pharmaceuticals | R$381.50B | 27.3x | 3.58 | R$53.64 | -3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Takeda Pharmaceutical Co | B3 | Healthcare | Pharmaceuticals | R$260.71B | 33.6x | 2.09 | R$86.85 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Cardinal Health | B3 | Healthcare | Pharmaceuticals | R$207.54B | 23.4x | 0.15 | R$836 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Alnylam Pharmaceuticals DRC | B3 | Healthcare | Pharmaceuticals | R$201.40B | -128.2x | -6.02 | R$73.87 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Teva Pharmaceutical Industries DRC | B3 | Healthcare | Pharmaceuticals | R$107.52B | -11.5x | 0.06 | R$44.36 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biogen DRC | B3 | Healthcare | Pharmaceuticals | R$97.78B | 11.4x | 0.46 | R$111.24 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Incyte | B3 | Healthcare | Pharmaceuticals | R$68.48B | 584.3x | -5.79 | R$209 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biomarin | B3 | Healthcare | Pharmaceuticals | R$65.35B | 21.7x | 0.15 | R$182.52 | 2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Perrigo Company | B3 | Healthcare | Pharmaceuticals | R$19.79B | -24.2x | 0.02 | R$146.55 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hypera | B3 | Healthcare | Pharmaceuticals | R$14.66B | 18.1x | -0.34 | R$23.28 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.7% Upside | Upgrade to Pro+ | |
Hypera SA ON | B3 | Healthcare | Pharmaceuticals | R$14.39B | 17.8x | -0.34 | R$22.78 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.7% Upside | Upgrade to Pro+ | |
Blau Farmaceutica | B3 | Healthcare | Pharmaceuticals | R$2.46B | 10x | -0.84 | R$13.68 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.1% Upside | Upgrade to Pro+ | |
Ouro Fino Saude Animal Particip | B3 | Healthcare | Pharmaceuticals | R$1.19B | 8.8x | 0.02 | R$22.47 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -7.4% Downside | Upgrade to Pro+ | |
PROFARMA ON | B3 | Healthcare | Pharmaceuticals | R$931.84M | 8x | 0.14 | R$7.68 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CM Hospitalar | B3 | Healthcare | Pharmaceuticals | R$353.71M | -0.3x | 0 | R$1.11 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |